Rubius Therapeutics will provide a strategic update
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that biologically modifies red blood cells to create an entirely new class of cellular drugs called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the company plans to provide a strategic update and host an investor conference call and webcast on Tuesday, September 13, 2022 at 7:00 p.m. 3:30 a.m. EDT.
Investor Conference Call and Webcast
An audio webcast will be available on the Events and Presentations page of the Investors and Media section of the Rubius Therapeutics website and can be accessed directly here. An archived webcast will be accessible for 90 days after the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of drugs called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically design and cultivate Red Cell Therapeutics™ which are selective, potent, ready-to-use allogeneic cell therapies for the potential treatment of multiple diseases in multiple therapeutic areas. Rubius’ initial goal is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities: potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named one of the 2021 Top Places to Work in Massachusetts by The Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.comfollow us on Twitter Where LinkedIn or like us on Facebook.
Investor and media contact
Lori Murray, Head of Corporate Affairs